Anti-CD40 Ligand Antibody Treatment Prevents the Development of Lupus-Like Nephritis in a Subset of New Zealand Black x New Zealand White Mice: Response Correlates with the Absence of an Anti-Antibody Response

Journal of Immunology

Volumn 157, Issue 7, 1996, Pages 3159-3164

  Early, Geoffrey S ^a   Zhao, Weiguo ^a   Burns, Christopher M ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CD40 LIGAND; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOSYNTHESIS; CROSS BREEDING; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; HAMSTER; HELPER CELL; HUMAN; IMMUNOLOGY; KIDNEY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MOUSE; MOUSE STRAIN; NEW ZEALAND BLACK MOUSE; PASSIVE IMMUNIZATION; PATHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CD40 LIGAND; CRICETINAE; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COOPERATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED NZB; MICE, INBRED STRAINS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0030267659     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Boumpas, D. T., H. A. Austin III, B. J. Fessler, J. E. Balow, J. H. Klippel, and M. D. Lockshin. 1995. Systemic lupus erythematosus: emerging concepts. I. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann. Intern. Med. 122:940.
2. Datta, S. K., H. Patel, and D. Berry. 1987. Induction of a cationic shift in IgG anti-DNA autoantibodies: role of T helper cells with classical and novel phenotypes in three murine models of lupus nephritis. J. Exp. Med. 165:1252.
3. - T helper cell lines augment the production of idiotypes shared by pathogenic anti-DNA autoantibodies in the NZB x SWR model of lupus nephritis. J. Immunol. 140:2215.
4. 1 murine SLE model. J. Immunol. 138:3185.
5. Naiki, M., B.-L. Chiang, D. Cawley, A. Ansari, S. J. Rozzo, B. L. Kotzin, and M. E. Gershwin. 1992. Generation and characterization of cloned helper T cell lines for anti-DNA responses in NZB H-2bm12 mice. J. Immunol. 149:4109.
6. Diamond, B., J. B. Katz, E. Paul, C. Aranow, D. Lustgarten, and M. D. Scharff. 1992. The role of somatic mutation in the pathogenic anti-DNA response. Annu. Rev. Immunol. 10:731.
7. Mohan, C., S. Adams, V. Stanik, and S. K. Datta. 1993. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exp. Med. 177:1367.
8. Mamula, M. J., S. Fatenejad, and J. Craft. 1994. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J. Immunol. 152:1453.
9. 1 mice with monoclonal antibody to L3T4. J. Exp. Med. 161:378.
10. 1 mice by treatment with monoclonal antibody to L3T4. J. Immunol. 138:3247.
11. + T cells is required to suppress autoimmunity. J. Immunol. 149:3083.
12. + T-cells and inversion of the CD4/CD8 T-cell ratio induced by anti-CD4 therapy. J. Rheumatol. 19:1845.
13. + T cell counts. Arthritis Rheum. 37:834.
14. Horneff, G., F. Emmrich, and G. R. Burmester. 1993. Advances in immunotherapy of rheumatoid arthritis: clinical and immunological findings following treatment with anti-CD4 antibodies. Br J. Rheumatol. 32:39.
15. Van der Lubbe, P. A., B. A. C. Dijkmans, H. M. Markusse, U. Nassander, and F. C. Breedveld. 1995. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum. 38:1097.
16. Ledbetter, J. A., J. B. Imboden, G. L. Schieven, L. S. Grosmaire, P. S. Rabinovitch, T. Lindsten, C. B. Thompson, and C. H. June. 1990. CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood 75:1531.
17. Gimmi, C. D., G. J. Freeman, J. G. Gribben, G. Gray, and L. M. Nadler. 1991. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 90:6586.
18. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, and J. A. Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173:721.
19. Norton, S. D., L. Zuckerman, K. B. Urdahl, R. Shefner, J. Miller, and M. K. Jenkins. 1992. The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J. Immunol. 149:1556.
20. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607.
21. Hathcock, K. S., G. Laszlo, H. B. Dickler, J. Bradshaw, P. Linsley, and R. J. Hodes. 1993. Identification of an alternative CTLA-4 ligand costimulalory for T cell activation. Science 262:905.
22. Tan, P., C. Anasetti, J. A. Hansen, J. Melrose, M. Brunvand, J. Bradshaw, J. A. Ledbetter, and P. S. Linsley. 1993. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177:165.
23. Finck, B. K., P. S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with CTLA4Ig. Science 265:1225.
24. Durie, F. H., T. M. Foy, S. R. Masters, J. D. Laman, and R. J. Noelle. 1994. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today 15:406.
25. DiSanto, J. P., J. Y. Bonnefoy, J. F. Gauchat, A. Fischer, and G. de Saint Basile. 1993. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 361:541.
26. Kotthauer, U., D. Graf, H. W. Mages, F. Briere, M. Padayachee, S. Malcolm, A. G. Ugazio, L. D. Notarangelo, R. J. Levinsky, and R. A. Kroczek. 1993. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 361:539.
27. Allen, R. C., R. J. Armitage, M. E. Conley, H. Rosenblatt, N. A. Jenkins, N. G. Copeland, M. A. Bedell, S. Edelhoff, C. M. Disteche, D. K. Simoneaux, W. C. Fanslow, J. Belmont, and M. K. Spriggs. 1993. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259:990.
28. Aruffo, A., M. Farrington, D. Hollenbaugh, X. Li, A. Milatovich, S. Nonoyama, J. Bajorath, L. S. Grosmaire, R. Stenkamp, M. Neubauer, R. L. Roberts, R. J. Noelle, J. A. Ledbetter, U. Francke, and H. D. Ochs. 1993. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72:291.
29. Conley, M. E., M. Larché, V. R. Bonagura, A. R. Lawton III, R. H. Buckley, S. M. Fu, E. Coustan-Smith, H. G. Herrod, and D. Campana. 1994. Hyper IgM syndrome associated with defective CD40-mediated B cell activation. J. Clin. Invest. 94:1404.
30. Noelle, R. J., M. Roy, D. M. Shepherd, I. Stamenkovic, J. A. Ledbetter, and A. Aruffo. 1992. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA 89:6550.
31. Foy, T. M., D. M. Shepherd, F. H. Durie, A. Aruffo, J. A. Ledbetter, and R. J. Noelle. 1993. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J. Exp. Med. 178:1567.
32. Durie, F. H., R. A. Fava, T. M. Foy, A. Aruffo, J. A. Ledbetter, and R. J. Noelle. 1993. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261:1328.
33. Mohan, C., Y. Shi, J. D. Laman, and S. K. Datta. 1995. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154:1470.
34. Hickey, W. F., N. K. Gonatas, H. Kimura, and D. B. Wilson. 1983. Identification and quantitation of T lymphocyte subsets found in the spinal cord of the Lewis rat during acute experimental allergic encephalomyelitis. J. Immunol. 131:2805.
35. Dawson-Saunders, B., and R. G. Trapp. 1994. Basic & Clinical Biostatistics. Appleton & Lange, Norwalk, p. 188.
36. Van den Eertwegh, A. J. M., R. J. Noelle, M. Roy, D. M. Shepherd, A. Aruffo, J. A. Ledbetter, W. J. A. Boersma, and E. Claassen. 1993. In vivo CD40-gp39 interactions are essential for thymus-dependent immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J. Exp. Med. 178:1555.